Inside China's Machine

Inside China’s Machine

China’s Humanoid Bet, Episode 3: Three Business Models Under One Label

Unitree, UBTech and AgiBot are compared as one industry, but the cash each collects shows different businesses, and, according to reports from July 2026, one of the three had disclosed no prospectus.

Inside China's Machine's avatar
Inside China's Machine
Nov 19, 2026
∙ Paid

Inside China’s Machine · China’s Humanoid Bet, Episode 3


Unitree’s final prospectus, filed in Shanghai on 14 August 2026, gives a plain number for the humanoid robots it sold in 2025: 5,215 units, RMB867.83m of humanoid revenue, and an average selling price of RMB166,400. UBTech’s interim report for the first half of 2026 gives no price. It does report a sales volume of 921 full-size humanoid robots and RMB590.3m of revenue from full-size humanoid “products and services.” Dividing one by the other gives about RMB641,000 a unit. That is our arithmetic, and because the filing’s line is “products and services”, it is not a price. AgiBot, the third name in every list of China’s humanoid makers, is private. It says its 2025 revenue passed RMB1bn, and press reports on 24 July 2026 said its Hong Kong prospectus had not yet been disclosed. Reports in October 2026 said a new funding round had pushed its listing back by about a year. The figure rests on the company’s own statement.

These numbers are easy to set side by side and call a price gap inside one industry, with one maker selling cheap robots and another selling dear ones. Our answer is different. The three companies sell three different things under one label. Revenue per unit does not show the difference. The cash does. At the end of 2025 Unitree was owed RMB61.9m by its customers, 3.64% of that year’s revenue, and its operating activities brought in RMB670.0m of net cash. On 30 June 2026 UBTech’s customers owed it RMB1,679.6m net, more than the RMB1,269.1m of revenue it booked in those six months. Its operating cash flow was negative by RMB749.5m in the half, and it was negative in each of the periods compared here (2024, 2025 and the first half of 2026). For AgiBot there is nothing to compare, so we compare only what exists.

All of these cash figures are company-wide. Neither filing splits receivables or cash flow by product, so none of them is a humanoid-only number. Even so, humanoids make up about half of each company’s revenue: about 51% of total revenue at Unitree in 2025 (our arithmetic) and 46.5% at UBTech in the first half of 2026 (as filed). At that share the company-wide gap bears on the humanoid comparison, though it does not tell us how much of the gap the humanoid line explains.

That matters to anyone who has to put a size on “the humanoid market.” A supplier forecasting actuator volumes, a lender setting terms, or an investor comparing the three is mixing different businesses if the starting point is unit counts or one company’s revenue per unit. Three questions should come first: what a unit is, what the money buys, and whether it arrives as cash. What would make this wrong is specific too. If UBTech’s receivables turned out to be mostly old balances from its non-humanoid lines, or if AgiBot filed numbers that looked like Unitree’s, the “three businesses” argument would shrink back toward one.

Keep reading with a 7-day free trial

Subscribe to Inside China's Machine to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2026 Inside China's Machine · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for writing, podcasting, and media founders.